Skip to main content

Table 2 Multivariate proportional hazards models (n = 103)

From: Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610

Endpoints

Covariate

Comparison

HR*

95% CI

p-value**

Overall Survival

VEGF

0-1 vs.

RL

  

2-3

1.314

(0.850, 2.030)

0.219

Treatment arm

STAD + RT arm vs.

RL

  

RT alone arm

1.268

(0.821, 1.959)

0.285

Age

< 71 vs.

RL

  

≥ 71

1.708

(1.112, 2.625)

0.015†

Combined Gleason Score

2-6 vs.

RL

  

7-10

1.416

(0.883, 2.270)

0.149

Clinical Stage

T2 vs.

RL

  

T3

1.026

(0.626, 1.681)

0.918

Distant Metastasis

VEGF

0-1 vs.

RL

  

2-3

1.090

(0.629, 1.889)

0.760

Treatment arm

STAD + RT arm vs.

RL

  

RT alone arm

1.472

(0.861, 2.517)

0.160

Age

< 71 vs.

RL

  

≥71

1.096

(0.631, 1.903)

0.740

Combined Gleason Score

2-6 vs.

RL

  

7-10

2.528

(1.358, 4.705)

0.003†

Clinical Stage

T2 vs.

RL

  

T3

0.819

(0.446, 1.504)

0.520

Local Progression

VEGF

0-1vs.

RL

  

2-3

1.160

(0.662, 2.030)

0.600

Treatment arm

STAD + RT arm vs.

RL

  

RT alone arm

1.306

(0.726, 2.349)

0.370

Age

< 71 vs.

RL

  

≥71

0.873

(0.496, 1.536)

0.640

Combined Gleason Score

2-6 vs.

RL

  

7-10

0.757

(0.426, 1.344)

0.340

Clinical Stage

T2 vs.

RL

  

T3

0.657

(0.361, 1.197)

0.170

Disease-free Survival

VEGF

0-1vs.

RL

  

2-3

0.859

(0.573, 1.286)

0.461

Treatment arm

STAD + RT arm vs.

RL

  

RT alone arm

2.102

(1.370, 3.227)

< 0.001†

Age

< 71 vs.

RL

  

≥ 71

0.932

(0.618, 1.407)

0.738

Combined Gleason Score

2-6 vs.

RL

  

7-10

1.717

(1.048, 2.813)

0.032†

Clinical Stage

T2 vs.

RL

  

T3

0.887

(0.539, 1.458)

0.626

Biochemical Failure

VEGF

0-1vs.

RL

  

2-3

1.041

(0.655, 1.652)

0.870

Treatment arm

STAD + RT arm vs.

RL

  

RT alone arm

1.995

(1.250, 3.186)

0.004†

Age

< 71 vs.

RL

  

≥ 71

0.770

(0.483, 1.229)

0.270

Combined Gleason Score

2-6 vs.

RL

  

7-10

1.403

(0.785, 2.508)

0.250

Clinical Stage

T2 vs.

RL

  
  

T3

0.961

(0.503, 1.837)

0.900

  1. * A hazard ratio (HR) is defined as the ratio of the estimated hazard for those with a variable value 1 to the estimated hazard for those with a variable value 0. A hazard ratio of 1 indicates no difference between two subgroups.
  2. ** P-values from Chi-square test using Cox (overall survival and disease-free survival) or Fine & Gray (distant metastasis, local progression, and biochemical failure) Proportional Hazards Model.
  3. † indicates the statistically significant at the significance level of 0.05.
  4. 1 patient without Gleason score is not included.
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us